# Impact of Empaglifozine on Cardiac Ectopic Fat

> **NCT03118336** · PHASE3 · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 56 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Empagliflozin 10Mg Tab

## Key facts

- **NCT ID:** NCT03118336
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-16
- **Primary completion:** 2019-02-07
- **Final completion:** 2020-02-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118336, "Impact of Empaglifozine on Cardiac Ectopic Fat". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03118336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*